Raphael Pharmaceutical (RAPH) Income towards Parent Company (2020 - 2026)
Raphael Pharmaceutical's (RAPH) quarterly Income towards Parent Company came in at -$199000.0 in Q2 2026, up 36.83% year-over-year from -$145440.8 in Q2 2025, and up 36.83% quarter-over-quarter from -$315000.0 in Q2 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Income towards Parent Company (2020 - 2026) Analysis & Trends
Raphael Pharmaceutical has disclosed Income towards Parent Company across 7 years of filings, most recently posting -$199000.0 for Q2 2026.
- In Q2 2026, Income towards Parent Company rose 36.83% year-over-year to -$199000.0; the TTM figure through Jun 2026 stood at -$1.2 million (up 3.92% YoY), while the FY2025 annual figure was -$1.2 million, up 17.5% from the prior year.
- Income towards Parent Company came in at -$199000.0 for Q2 2026 at Raphael Pharmaceutical, up from -$315000.0 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $134000.0 in Q4 2023 to a low of -$1.4 million in Q3 2022.
- Average Income towards Parent Company over 5 years is -$472285.7, with a median of -$356500.0 recorded in 2024.
- Year-over-year, Income towards Parent Company surged 112.14% in 2023 and plunged 394.03% in 2024.
- Over 5 years, Income towards Parent Company stood at -$1.1 million in 2022, then jumped by 112.14% to $134000.0 in 2023, then sank by 394.03% to -$394000.0 in 2024, then increased by 20.05% to -$315000.0 in 2025, then surged by 36.83% to -$199000.0 in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$199000.0 in Q2 2026, -$315000.0 in Q2 2025, and -$394000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -199,000.00 |
| Jun 30, 2025 | -315,000.00 |
| Dec 31, 2024 | -394,000.00 |
| Sep 30, 2024 | -319,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -547,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Sep 30, 2023 | -729,000.00 |
| Jun 30, 2023 | -419,000.00 |
| Mar 31, 2023 | -258,000.00 |
| Dec 31, 2022 | -1.10 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -612,000.00 |
| Mar 31, 2022 | -175,000.00 |
| Dec 31, 2021 | -574,000.00 |
| Sep 30, 2021 | -418,000.00 |
| Jun 30, 2021 | -385,000.00 |
| Mar 31, 2021 | -252,000.00 |
| Dec 31, 2020 | -227,000.00 |